Related Experiment Video
Updated: Jan 9, 2026
Regulation of Hormone Secretion
PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis
Xuehui Hong1, Ruipeng Song1, Huiwen Song2
1Key Laboratory of Hepatosplenic Surgery, Ministry of Education, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Background:
Mounting epidemiological evidence supports a role for phosphatase and tensin homologue (PTEN)-T cell leukaemia 1 (Tcl1) signalling deregulation in hepatocarcinogenesis.
Objective:
To determine the molecular and biochemical mechanisms by which the PTEN/Tcl1 axis regulates the pentose phosphate pathway (PPP) in hepatocellular carcinoma (HCC).
Methods:
We compared levels of PTEN and glucose-6-phosphate dehydrogenase (G6PD) mRNA in human HCC and healthy liver tissue. We measured PPP flux, glucose consumption, lactate production, nicotinamide adenine dinucleotide phosphate (NADPH) levels and lipid accumulation. We investigated the PTEN/Tcl1 axis using molecular biology, biochemistry and mass spectrometry analysis. We assessed proliferation, apoptosis and senescence in cultured cells, and tumour formation in mice.
Results:
We showed that PTEN inhibited the PPP pathway in human liver tumours. Through the PPP, PTEN suppressed glucose consumption and biosynthesis. Mechanistically, the PTEN protein bound to G6PD, the first and rate-limiting enzyme of the PPP and prevented the formation of the active G6PD dimer. Tcl1, a coactivator for Akt, reversed the effects of PTEN on biosynthesis. Tcl1 promoted G6PD activity and also increased G6PD pre-mRNA splicing and protein expression in a heterogeneous nuclear ribonucleoprotein (hnRNPK)-dependent manner. PTEN also formed a complex with hnRNPK, which inhibited G6PD pre-mRNA splicing. Moreover, PTEN inactivated Tcl1 via glycogen synthase kinase-3β (GSK3β)-mediated phosphorylation. Importantly, Tcl1 knockdown enhanced the sensitivity of HCC to sorafenib, whereas G6PD knockdown inhibited hepatocarcinogenesis.
Conclusions:
These results establish the counteraction between PTEN and Tcl1 as a key mechanism that regulates the PPP and suggest that targeting the PTEN/Tcl1/hnRNPK/G6PD axis could open up possibilities for therapeutic intervention and improve the prognosis of patients with HCC.
Insights
The phosphatase and tensin homologue (PTEN) protein inhibits the pentose phosphate pathway (PPP) in liver cancer, but T cell leukaemia 1 (Tcl1) counteracts this effect. Targeting this axis may offer new therapies for hepatocellular carcinoma (HCC).
Area of Science:
- Molecular biology and biochemistry of cancer signaling pathways.
- Hepatocellular carcinoma (HCC) pathogenesis and therapeutics.
Background:
- Epidemiological studies indicate that dysregulation of phosphatase and tensin homologue (PTEN) and T cell leukaemia 1 (Tcl1) signaling contributes to liver cancer development.
- Understanding the PTEN/Tcl1 axis is crucial for deciphering hepatocellular carcinoma (HCC) mechanisms.
Purpose of the Study:
- To elucidate the molecular and biochemical mechanisms by which the PTEN/Tcl1 axis regulates the pentose phosphate pathway (PPP) in hepatocellular carcinoma (HCC).
- To investigate the role of PTEN and Tcl1 in controlling metabolic pathways critical for HCC progression.
Main Methods:
- Comparative analysis of PTEN and glucose-6-phosphate dehydrogenase (G6PD) mRNA levels in human HCC and healthy liver tissues.
- Measurement of PPP flux, glucose consumption, lactate production, NADPH levels, and lipid accumulation.
- Utilized molecular biology, biochemistry, and mass spectrometry to study the PTEN/Tcl1 axis; assessed cell proliferation, apoptosis, senescence, and tumor formation in mice.
Main Results:
- PTEN was found to inhibit the PPP, suppressing glucose consumption and biosynthesis in human liver tumors by binding to and preventing the dimerization of G6PD.
- Tcl1 reversed PTEN's effects, promoting G6PD activity and expression via heterogeneous nuclear ribonucleoprotein K (hnRNPK)-dependent mechanisms; PTEN also inhibited G6PD splicing and inactivated Tcl1.
- Tcl1 knockdown sensitized HCC to sorafenib, while G6PD knockdown inhibited hepatocarcinogenesis, highlighting their critical roles.
Conclusions:
- The counteraction between PTEN and Tcl1 is a key regulator of the PPP in HCC.
- Targeting the PTEN/Tcl1/hnRNPK/G6PD axis presents a potential therapeutic strategy for improving HCC patient prognosis.
- This axis offers novel avenues for therapeutic intervention in hepatocellular carcinoma.
Related Concept Videos
Regulation of Hormone Secretion
Humoral...
Hormonal Regulation
Overview of Secretory Vesicles
Various proteins regulate the aggregation of molecules inside the secretory vesicles. Chromogranins...
Insulin Secretory Vesicles
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Feedback Inhibition